Achieve Life Sciences Presents Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting, March 12th, 2020
ORCA-1 Program Infographic. Click image to enlarge.
Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial. 3.0 mg, 3 times daily selected as dose for future clinical development.